Radius Health Inc.

NASDAQ:RDUS   3:59:55 PM EDT
10.47
+0.10 (+0.96%)
Products

Menarini Group And Radius Health Submit New Drug Application To The U.S. FDA For Elacestrant

Published: 06/22/2022 20:37 GMT
Radius Health Inc. (RDUS) - Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant.
Radius Health Inc - Plan to File Marketing Authorization Application for Elacestrant in Eu in 2h 2022.
Radius Health Inc - Priority Review Requested; If Accepted, Anticipate an 8-month FDA Review.
Radius Health Inc - Menarini Plans to Use Its Fully Owned Subsidiary in U.S., Stemline Therapeutics, to Commercialize Elacestrant If Approved by FDA.